Stocktoria

Janux Therapeutics, Inc. JANX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-06-11

Janux Therapeutics, Inc. statistics & valuation

Market cap$911.1M
P / S91.1×
P / B1.0×
Net margin-1136.2%
Return on equity-11.9%
FCF margin-832.8%
Return on capital-16.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-898.30% -732.20% -721.20% -651.60% -1136.20% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-905.40% -779.00% -902.90% -933.60% -1576.70% 202020212022202320242025
Return on equity (%)
-8.90% -19.70% -16.90% -6.70% -11.90% 202020212022202320242025
Shares outstanding
1.0M 41.2M 41.6M 46.3M 59.1M 62.0M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-41.80% -8.60% -17.30% -15.30% -6.50% -11.30% 202020212022202320242025
Free cash flow margin (%)
-507.50% -573.20% -648.60% -417.20% -832.80% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$1.39 -$1.52 -$1.32 -$1.28 -$1.83 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-1576.7%-933.6%-902.9%-779.0%-905.4%—
Net margin-1136.2%-651.6%-721.2%-732.2%-898.3%—
FCF margin-832.8%-417.2%-648.6%-573.2%-507.5%—
Return on assets-11.3%-6.5%-15.3%-17.3%-8.6%-41.8%
Return on equity-11.9%-6.7%-16.9%-19.7%-8.9%46.3%
Current ratio39.0459.2126.8020.1429.465.05

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.